Publications and project deliverables
In the context of the COVIRNA project, consortium members developed the following publications:
- FIMICS: A panel of long noncoding RNAs for cardiovascular conditions (Pub.: 19 Jan 2023)
- Association of miR-144 levels in the peripheral blood with COVID-19 severity and mortality (Pub.: 21 Nov 2022)
- (Epi)transcriptomics in cardiovascular and neurological complications of COVID-19 (Pub.: 28 July 2022)
- Evidence for biological age acceleration and telomere shortening in COVID-19 survivors (Pub.: 7 June 2021)
- Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129 (Pub.: 11 Apr 2021)
- Lack of evidence of angiotensin-converting enzyme 2 expression and replicative infection by SARS-CoV-2 in human endothelial cells (Pub.: 6 Jan 2021)
- Joining European scientific forces to face pandemics (Pub.: 4 Dec 2020)
- Call to action for the cardiovascular side of COVID-19 (Pub.: 13 Apr 2020)
In its 30 months of activity the COVIRNA project produced a number of deliverables. Below you can find a selection of public deliverables:
- Mediation analysis for understanding direct and mediated effects of lncRNA (D3.2)
- Prediction of MACE (Major Adverse Cardiovascular Events) (D3.3)
- Disease mortality classification (D3.4)
- Design and synthesis of GapmeRs or siRNAs and of expression vectors for target lncRNAs (D4.1)
- Transcriptomic alterations in SARS-COV-2 infected cardiovascular cells (D4.2)
- Functional analysis of inflammatory and vascular cell types (D4.3)
- Project logo, flyer and website (D6.1)
- Communication, dissemination and exploitation plan (D6.2)
- Project video (D6.3)
- Final dissemination event (D6.4)
Communication and dissemination
We committed to connect with all stakeholders, from scientists, clinicians and health managers to patient organisations and the general public. We developed a number of dissemination materials to explain the COVIRNA project, its objectives, methodology, progress and results.
- The project video presents COVIRNA in a simple but compelling language.
- The flyer is a visual two-pager to introduce COVIRNA to the general public.
Our newsletters provided news and updates on the project.
- Newsletter – Issue n. 1 (June 2021)
- Newsletter – Issue n. 2 (Dec 2021)
- Newsletter – Issue n. 3 (June 2022)
- Newsletter – Issue n. 4 (Feb 2023)
- Newsletter – Issue n. 5 (Apr 2023)
We organised events and webinars to present our project to different audiences.
- The key learnings from the session ‘Towards personalised medicine – an innovative diagnostic tool to identify cardiovascular complications in COVID-19 patients‘ during the EHMA 2021 Annual Conference (Sept 2021).
- The report of the session ‘The potential of innovative diagnostic tools: personalised disease management for improved health outcomes in COVID-19 patients’ during the EHMA 2022 Annual Conference (June 2022)
- The report and video recording of the webinar ‘Addressing unmet clinical needs, practices and patient outcomes: the impact of EU-funded projects‘ (Jan 2023)
- The report and video recording of the webinar ‘Patient-centred approaches to Long COVID‘ (Mar 2023)
- The report of the final conference ‘Improving personalised care and patient outcomes through molecular diagnostics and therapy‘ (Apr 2023)
In line with the requirements of the granting authority, we produced technical reports that detail the work conducted during the specific reporting periods.
- Publishable summary – Reporting Period 1 (November 2020 – October 2021)
The report provides an overview of the work carried out in the first year of the project, including achievements, expected results and potential impact.
- Publishable summary – Reporting Period 2 (November 2021 – April 2023)
The report provides an overview of the work carried out, including results and impact achieved.